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Conventionally, osteoporosis medication is classified 
into anti-resorptive drugs, anabolic agents or 
stimulators of bone formation, and agents with a 
dual or complex action on bone.
Anti-resorptive agents
Calcium and vitamin D
Treatment of osteoporosis with calcium and vitamin D only is 
associated with a modest reduction in fracture risk, and calcium 
with or without vitamin D has also been a mandatory component 
in all drug trials assessing the anti-fracture efficacy of potent 
bone-active drugs. Calcium and vitamin D have generally been 
regarded as safe and largely without side-effects when used in their 
recommended doses – supplemented as approximately 600 mg 
elemental calcium per day (to ensure a total daily intake of about 
1 000 mg per day) and 800 - 1 200 IU vitamin D per day. Higher 
doses of vitamin D may be used in pregnancy and lactation, and to 
treat proven osteomalacia.
Constipation is not uncommon in patients on calcium 
supplements, especially when calcium carbonate is used, and this 
is an important cause of poor drug adherence. An increased risk 
of renal stones (10 - 15%) has been reported, but there is a paucity 
of controlled or prospective data. Hypercalcaemia generally only 
occurs when high and prolonged doses of vitamin D or one of 
its active metabolites (not recommended for routine osteoporosis 
treatment) are used.
Bolland et al.[2] recently published a meta-analysis suggesting that 
high-dose calcium supplementation in postmenopausal women with 
osteoporosis is associated with an increased risk of cardiovascular 
disease (CVD). On further scrutiny of the paper it is, however, quite 
clear that the increased risk of CVD was only evident in subjects who 
consumed at least 800 mg calcium per day in their diet, in addition to 
the high-dose supplementation. Furthermore, results of the recently 
published Canadian Multicentre Osteoporosis Study, which involved 
10-year longitudinal follow-up of over 9 000 participants, showed that 
calcium supplementation of up to 1 000 mg per day was associated 
with no harm, and in fact with reduced mortality, in women.[3]
It is therefore fair to conclude that:
• Whenever possible, an adequate dietary intake of calcium is 
preferable to supplementation.
• Calcium should not be supplemented in those with an adequate 
dietary intake.
• When used in recommended doses to prevent/treat osteoporosis, 
calcium and vitamin D are safe.
• Care should be taken when considering supplementing patients 
with established CVD or impaired renal function.
Menopausal hormone therapy
Menopausal hormone (oestrogen with or without progestin) therapy 
(MHT) has been convincingly shown to increase bone mineral density 
(BMD) and to reduce clinical fracture risk at all sites (including the 
spine and hip), not only in subjects at high risk of sustaining an 
osteoporotic fracture, but specifically in those with a near-normal BMD 
and no prior fracture. This was suggested by numerous observational 
studies, conclusively proven by the Women’s Health Initiative (WHI),[4] 
and further corroborated by the large National Osteoporosis Risk 
Assessment (NORA)[5] and Million Women Studies.[6]
Initial results from the WHI, however, suggested that MHT was 
associated with an increased risk of CVD, thrombo-embolic disease 
(TED), stroke and breast cancer.[7] These agents have therefore largely 
been abandoned as first-line treatment for osteoporosis by most 
regulatory authorities. Objections to the conclusions drawn from the 
WHI have again been highlighted recently[8] and include:
• Incorrect or inappropriate study design (e.g. heavy emphasis was 
placed on a single, unvalidated tool to assess the safety of MHT, the 
so-called ‘global index’).
• Poor data analysis (e.g. lack of distinction between nominal and 
adjusted risk, and emphasis on relative as opposed to absolute risk 
– e.g. emphasising the 2-fold increase in TED that accompanies the 
use of MHT, yet omitting the fact that the absolute risk increases 
from 1 in 1 000 postmenopausal women to 2 in 1 000 women).
• Disregard for the high rates of discontinuation in the active 
treatment arm (42%) and crossover to active treatment in the 
placebo arm (11%).
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• Extrapolation of data obtained in 64-year-old subjects (the average 
age of women included in the WHI) to young 50-year-old 
individuals – stratification of especially CVD according to age/
time since menopause has subsequently been shown to be critical.
• Inadequate differentiation between data obtained from the 
oestrogen-only and the oestrogen-plus-progestin study arms – 
e.g. available evidence suggests that the increased risk of breast 
cancer associated with the use of MHT is entirely limited to the 
use of oestrogen plus progestin, and does not apply to the use of 
oestrogen-only therapy.
• Generalisation about the specific progestin used in combined 
hormone therapy.
• Disregard for the protective role of transdermal MHT on the 
development of the metabolic syndrome and its associated vascular 
complications.
A detailed discussion of this debate is beyond the scope of this 
paper. Suffice to reiterate the recommendations of the National 
Osteoporosis Foundation of South Africa (NOFSA) guidelines, 
published in 2010,[1] namely:
• MHT should only be initiated for specific indications in subjects 
without contraindications to its use (e.g. current breast cancer, 
undiagnosed genital bleeding, current deep-vein thrombosis, 
untreated hypertension/CVD).
• In the absence of contraindications, the use of MHT in women 
aged 50 - 60 years is safe and appropriate to manage osteoporosis 
– in fact, in individuals with menopausal symptoms it should be 
regarded as the drug of choice.
• It is best not to initiate MHT after age 60 years for the sake of 
skeletal protection only; continued use of MHT after age 60 
may, however, be considered if other treatment options are 
contraindicated.
• If fracture protection is sought, doses of hormone therapy known 
to provide fracture protection (i.e. 0.625 mg/day conjugated equine 
oestrogen or equivalent) should be used. Low-dose hormone 
therapy has been shown to protect against loss of BMD, but 
fracture data are still awaited.
• A reduction in BMD may occur once MHT is discontinued, and 
treatment with another bone-active drug should therefore be 
considered at that stage.
Calcitonin
Calcitonin was previously reserved for individuals who could not 
tolerate more effective therapy (e.g. with a creatinine clearance 
rate <30 ml/min).[1] Up to a third of patients experienced nausea, 
diarrhoea and flushing. Calcitonin has recently been associated 
with a 1 - 3% increase in the risk of systemic malignancies and has 
therefore been withdrawn from the market as a useful and safe agent 
to treat osteoporosis.[9]
Bisphosphonates
The bisphosphonates (BPs) are universally regarded as a first-line 
treatment for osteoporosis in postmenopausal and elderly women, 
in men, and in a number of secondary osteoporoses, including 
glucocorticoid-induced osteoporosis.
Oral BPs may cause an erosive oesophagitis (especially if taken 
incorrectly) with nausea, heartburn, chest pain and vomiting. 
The intravenous BPs may precipitate acute renal failure (when 
rapidly injected) and have been associated with a severe flu-like 
syndrome (usually a first-dose, acute-phase reaction that responds 
to paracetamol or non-steroidal anti-inflammatory drugs), 
hypocalcaemia (especially in the presence of vitamin D deficiency), 
or diffuse bone pains. Skeletal retention of BPs is very long (terminal 
half-life >10 years) and, under certain circumstances, even lifelong. 
Concerns regarding fetal safety have therefore been expressed where 
women of child-bearing age have been subjected to many years 
of BP treatment. No conclusive data that BPs are harmful to the 
fetus have been forthcoming, but clinicians should be alerted 
regarding unnecessary and unproven treatment with BPs of younger 
women with isolated, modest decreases in BMD. Initial concerns 
about oesophageal cancer with oral BPs and atrial fibrillation with 
intravenous zoledronic acid have not been substantiated by a recent 
Food and Drug Administration audit.[10-13] Two other side-effects, 
namely osteonecrosis of the jaw (ONJ) and atypical fragility fractures 
(AFFs), however, warrant discussion.
The first report of an association between ONJ and the use of 
BPs was published in 2004, and it has subsequently become clear 
that up to 80% of cases occurred in patients with an underlying 
malignancy (often myeloma or breast cancer), and 90% were 
receiving high-dose intravenous BPs.[14-16] In this regard, it is 
important to reiterate that such patients generally receive a dose 
of BPs that is ten-fold higher than doses used to treat osteoporosis. 
Other predisposing factors include dento-alveolar surgery and local 
oral disease (inflammation, cancer), systemic factors (advanced 
age, diabetes, renal impairment, smoking, alcohol), and a genetic 
predisposition. In patients with osteoporosis treated with BPs, the 
incidence of ONJ is extremely low (0.01 - 0.0004%) and probably 
not different from that of the general population. For this reason, 
NOFSA recommends[1] that:
• Patients and dentists need to be reassured that ONJ is extremely 
rare in association with the doses of BPs approved for the 
treatment of osteoporosis. Whether BPs are administered orally or 
intravenously does not seem to affect the risk of ONJ.
• Good oral hygiene and regular dental visits are advisable. It is, 
however, not necessary to recommend a dental examination before 
starting BP therapy for osteoporosis. If major dental surgery is 
anticipated, it seems prudent to suggest that this be completed 
before starting BP treatment.
• In subjects already receiving a BP, dental implant surgery is not 
contraindicated. Some suggest stopping the BP, but there are no 
data to support this. The use of bone turnover markers has been 
suggested, but cannot be supported.
• In subjects with established ONJ, surgical treatment should 
be conservative, infection should be treated with appropriate 
antibiotics, and pain relief is important, as is referral to an 
experienced maxillofacial surgeon. Given the availability 
of alternative bone-active agents, it is probably reasonable to 
discontinue the BP.
Following earlier suggestions by Ott[17] of atypical fractures after 
long-term alendronate therapy, in 2005 Odvina et al.[18] (senior 
author Charles Pak) described nine cases of severely suppressed 
bone turnover with spontaneous non-spine fractures and delayed 
fracture healing. Subsequently numerous case reports, retrospective 
reviews and register-based national cohort studies have confirmed 
an increased prevalence of AFFs in patients receiving alendronate, 
prompting regulatory bodies in Europe, the UK and the USA to alert 
healthcare professionals to this association and to insist that product 
information for alendronate be updated to include a warning about 
AFFs. This syndrome is characterised by:[17-20]
• A history of chronic alendronate use – limited data are available 
for the other BPs in support of a causal association with AFFs, but 
this probably reflects their lower use and the limited availability of 
long-term data.
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• AFFs most often involve areas rich in cortical bone (e.g. 
subtrochanteric or diaphyseal femur, pelvic bones), and are 
sustained either spontaneously or following minimal trauma.
• A prodrome of pain and tenderness over the impending fracture site.
• Concomitant use of glucocorticoids or oestrogen.
• Quantitative bone histology shows severely suppressed bone 
turnover, similar to the so-called adynamic bone disease found in 
a subset of patients with chronic renal failure; serum biomarkers 
of bone turnover are usually decreased, but often not as markedly 
as the bone histology.
• Radiographs may show typical cortical stress fractures or a simple 
transverse or oblique fracture of the femur with beaking of the 
cortex and diffuse cortical thickening of the proximal femoral shaft.
• Bilateral disease is not infrequent – contralateral pathology may 
be evident on clinical assessment (e.g. tenderness over the femur 
shaft), standard radiographs or an isotope bone scan.
• History of delayed or absent fracture healing.
Correct management of this syndrome is difficult, given the current 
state of our knowledge. Clearly BP treatment needs to be discontinued 
in the event of an atypical fracture, and an alternative anti-fracture 
agent should be considered. Contralateral disease should be sought 
and may require intervention (e.g. prophylactic orthopaedic 
pinning). Appropriate measures to prevent the development of AFFs 
include greater awareness of the condition and possibly limiting the 
duration of BP treatment to 4 - 5 years. In this regard it is, however, 
imperative to note that BP-induced AFF is a rare phenomenon, with 
an estimated prevalence of around 1 in 1 000. Moreover, limiting 
BP treatment to <3 years has been shown to provide ineffective 
protection against conventional osteoporotic fractures. Much more 
harm may therefore emanate from the indiscriminate, premature 
discontinuation of BP treatment in an attempt to prevent AFF. 
There are no clear recommendations to circumvent this conundrum 
at present, other than to suggest that any osteoporosis treatment 
strategy should be reassessed following 4 - 5 years of BP therapy 
and the need for continued treatment with a BP or alternative anti-
fracture agent appraised.
Stimulators of bone formation
Teriparatide
Parathyroid hormone (PTH 1-84) or the PTH fragment (hPTH 1-34), 
teriparatide, have been shown to be potent anabolic agents that 
stimulate osteoblastic bone formation (peaks within 3 - 6 months 
and is maintained for 18 - 24 months) and reduce vertebral and 
non-vertebral fracture risk. Osteoclastic bone resorption is also 
stimulated, but since this only peaks some 12 - 24 months later, an 
‘anabolic window’ is created that results in a very significant increase 
in areal and volumetric bone mass, size and strength.[21-27]
Teriparatide is used in the management of osteoporosis, but only 
for specific indications – these include failed anti-resorptive therapy, 
severe fracturing disease, and glucocorticoid-induced osteoporosis 
with a markedly decreased BMD. These specific indications have 
been published in position papers by NOFSA.[24,25] The use of 
teriparatide is limited by its expense and certain contraindications. 
Long-term studies with high-dose PTH, administered lifelong to 
Fischer 344 rats, have demonstrated a dose-related increase in 
the risk of osteogenic sarcoma. All primate studies have failed to 
show a similar association, and osteosarcomas do not occur with 
increased frequency in humans with primary hyperparathyroidism, 
nor have they been noted in any of the trials performed in many 
thousands of patients treated with PTH for >3 years. To date, a 
single case of osteosarcoma has been reported in >300 000 patients 
treated worldwide with PTH. It is therefore very unlikely that 
teriparatide is associated with any increased risk of osteogenic 
sarcoma. Nonetheless, regulatory bodies worldwide have limited the 
use of teriparatide to treat osteoporosis to an 18 - 24-month period 
(18 months in South Africa), following which alternative agents (e.g. 
a bisphosphonate) should be employed to preserve bone mass, which 
otherwise decreases rapidly after teriparatide has been discontinued. 
It has also been recommended that teriparatide should not be used in 
subjects with an increased risk of developing osteosarcoma (e.g. prior 
skeletal radiation), in patients with malignancy, in growing children, 
in pregnancy and lactation, in subjects with hypercalcaemia, and in 
individuals with impaired renal function (glomerular filtration rate 
<30 ml/min).
Nausea, headaches and leg cramps are not infrequent in patients 
treated with teriparatide. Hypercalcaemia occurs in up to 10% of 
patients, but hypercalciuria, hyperuricaemia and renal stone disease 
are rare.[21-27]
Drugs with dual or complex actions 
on bone
Strontium ranelate
Strontium ranelate has a dual mode of action resulting in the 
stimulation of bone formation and inhibition of resorption. Large 
clinical studies such as the pivotal Spinal Osteoporosis Therapeutic 
Intervention (SOTI)[28] and Treatment of Peripheral Osteoporosis 
(TROPOS)[29] trials have demonstrated that this agent significantly 
increases BMD and decreases fracture risk at both the spine and hip 
over prolonged periods of time. Furthermore, the drug is effective in 
patients with only a modest decrease in BMD and also in the very old 
(>80 years).[28-30]
Gastrointestinal side-effects, notably nausea and diarrhoea, occur 
frequently in the first 3 months of treatment but can usually be 
managed by slow titration of the dose. In pooled data from the 
SOTI and TROPOS studies, a small but significant (0.9% v. 0.6%) 
increased risk of venous thrombo-embolism (VTE) was documented, 
and although the cause of this is unknown, it is recommended that 
strontium ranelate is best avoided in patients at risk of VTE.
During post-marketing surveillance of patients treated with 
strontium ranelate, cases of drug reaction with eosinophilia and 
systemic symptoms (DRESS) syndrome as well as toxic epidermal 
necrolysis and Stevens-Johnson syndrome were reported[31] – to 
date, <2 dozen cases from a total of more than a half million 
patient years of exposure have been documented. The DRESS drug 
hypersensitivity syndrome is not unique to strontium ranelate and is 
associated with a large number of commonly used drugs including 
the anti-epileptics and allopurinol. Since systemic involvement 
(hepatitis, nephritis, endocarditis) following continued use can be 
fatal, it is important to be aware of the association and to discontinue 
the drug if any significant skin disorder occurs within 2 - 3 months 
after initiating treatment.
In April 2013, the European Medicines Agency (EMA) 
released their report of a routine assessment conducted by their 
Pharmacovigilance Risk Assessment Committee (PRAC) on pooled 
data from seven studies in >7 500 women treated with strontium 
ranelate. Compared with placebo, those treated with strontium 
ranelate showed an increased risk of non-fatal myocardial infarction 
(1.7 v. 1.1%, with a relative risk of 1.6; 95% confidence interval 
1.07 - 2.38).[32] This increased risk was confined to patients with 
poorly controlled hypertension (blood pressure >160/90 mmHg) 
or known ischaemic heart disease (IHD). Based on the report of 
the PRAC, the EMA Committee for Medical Products of Human 
Use made certain recommendations regarding the indications for 
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and contraindications to strontium ranelate in the treatment of 
osteoporosis.[32] Further evaluations are being conducted. Locally, 
these findings have been submitted to the Medicines Control Council 
(MCC), which is currently reviewing the data.
NOFSA’s views on the matter can be summarised as follows:
• Strontium ranelate is a useful anti-fracture agent to manage 
patients with osteoporosis or those at high fracture risk, if the 
following precautions are adhered to:
• Strontium ranelate should not be used in patients with a current 
or past history of IHD, peripheral arterial disease (PAD) and/
or CVD, or in patients with uncontrolled (>160/90 mmHg) or 
untreated hypertension.
• Before embarking on treatment with strontium ranelate, 
the presence of risk factors for CVD (e.g. dyslipidaemia, 
dysglycaemia/diabetes, obesity, hypertension, smoking) should 
be carefully assessed. If present, treatment with strontium 
ranelate should be undertaken only after careful consideration.
• Risk factors for and/or the presence of CVD should be assessed 
at regular intervals during treatment, and treatment should be 
discontinued if the patient develops uncontrolled hypertension, 
IHD, CVD or PAD.
These recommendations of NOFSA will of course all be subject to the 
final recommendations from the MCC.
Conclusions
If it is used appropriately, the benefits of treatment of osteoporosis far 
outweigh the risks. Every patient with osteoporosis therefore deserves 
a thorough assessment and in-depth consideration of therapeutic 
options before initiating the most appropriate, most effective and 
safest treatment.
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